A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2011
11/17/2011	US20110280922 Devices and methods for treating and/or preventing diseases
11/17/2011	US20110280921 Antibacterial hydrogel and use thereof in orthopedics
11/17/2011	US20110280916 Stable hydroalcoholic oral spray formulations and methods
11/17/2011	US20110280909 Method and system for effecting changes in pigmented tissue
11/17/2011	US20110280903 Immunostimulatory combinations
11/17/2011	US20110280893 Synthetic lipid a derivative
11/17/2011	US20110280886 Treating cancer by modulating mnk
11/17/2011	US20110280882 Leukolectins and uses thereof
11/17/2011	US20110280876 Mutated netrin - 4, fragments thereof and their use as medicines
11/17/2011	US20110280874 Modulating angiogenesis
11/17/2011	US20110280867 Heterocyclic aspartyl protease inhibitors
11/17/2011	US20110280865 Ets-2 Biomarkers for Fibrotic Diseases and Uses Thereof
11/17/2011	US20110280863 Methods and compositions for the detection and treatment of preeclampsia
11/17/2011	US20110280861 Method for mir-125a in promoting hematopoietic stem cell self renewal and expansion
11/17/2011	US20110280860 Pharmaceutical compositions comprising monoterpenes
11/17/2011	US20110280859 Preventing and treating sepsis
11/17/2011	US20110280857 Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds
11/17/2011	US20110280855 Vitamin c compositions
11/17/2011	US20110280852 Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline
11/17/2011	US20110280847 Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth
11/17/2011	US20110280842 Methods of reprogramming cells
11/17/2011	US20110280841 Electroprocessing in Drug Delivery and Cell Encapsulation
11/17/2011	US20110280832 Eotaxin-2 (ccl24) inhibitors in inflammatory, autoimmune, and cardiovascular disorders
11/17/2011	US20110280831 Combinations comprising methotrexate and dhodh inhibitors
11/17/2011	US20110280829 Low Molecular Weight Sulphated Polysaccharides as Candidates for Anti-Angiogenic Therapy
11/17/2011	US20110280825 Extracorporeal devices and methods of treating complications of pregnancy
11/17/2011	US20110280824 Furanone Copolymers
11/17/2011	US20110280813 Neuraminidase inhibitors and uses thereof
11/17/2011	US20110280812 Flavor-enhancing amide compounds
11/17/2011	US20110280809 Pdia4, target of cytopiloyne derivatives, for tumor diagnosis and treatment
11/17/2011	US20110280808 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
11/17/2011	US20110280807 Methods and Models for Stress-Induced Analgesia
11/17/2011	US20110280799 Nanocells for diagnosis and treatment of diseases and disorders
11/17/2011	US20110280763 Light-activated disinfection system
11/17/2011	US20110277339 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
11/17/2011	DE102010028874A1 Isolating stilbenoid with solvent immiscible in water, useful for producing cosmetics, food, dietary supplements, pharmaceuticals and animal feed, comprises reducing the water content of the solvent
11/17/2011	DE102010022174A1 Neue Darreichungsformen für Cineol New forms of cineole
11/17/2011	DE102010020567A1 Metallkomplexe Metal complexes
11/17/2011	CA2835596A1 Benzo- or pyrido-imidazole derivative
11/17/2011	CA2835489A1 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
11/17/2011	CA2816925A1 Nucleic acid-containing lipid particles and related methods
11/17/2011	CA2805086A1 Antisense modulation of interleukins 17 and 23 signaling
11/17/2011	CA2800578A1 Nitrogen-heterocyclic compounds as phosphodiesterase 10 inhibitors
11/17/2011	CA2800577A1 Therapeutic liposomes and methods for producing and using the same
11/17/2011	CA2800497A1 Ratiometric combinatorial drug delivery
11/17/2011	CA2799495A1 Pyrimidine compounds that inhibit anaplastic lymphoma kinase
11/17/2011	CA2799431A1 Cancer prevention and treatment methods based on dietary polyamine content
11/17/2011	CA2799420A1 Compositions and methods for treating neoplasia, inflammatory disease and other disorders
11/17/2011	CA2799416A1 Compositions and methods for targeting a3g:rna complexes
11/17/2011	CA2799407A1 Alcohol-resistant oral pharmaceutical form
11/17/2011	CA2799403A1 Compositions and methods for treating leukemia
11/17/2011	CA2799397A1 Composition for reducing absorption of dietary fat
11/17/2011	CA2799381A1 Male contraceptive compositions and methods of use
11/17/2011	CA2799204A1 Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
11/17/2011	CA2799183A1 Therapeutic regimens
11/17/2011	CA2799162A1 Treatment of mci and alzheimer's disease
11/17/2011	CA2799156A1 Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases
11/17/2011	CA2799154A1 Indazole inhibitors of kinase
11/17/2011	CA2799146A1 Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine
11/17/2011	CA2799121A1 Substituted 8-alkoxy-2-aminotetralin derivatives, and use thereof
11/17/2011	CA2799110A1 Pharmaceutical dosage form comprising one or more antiretroviral active ingredients
11/17/2011	CA2799099A1 New cyclohexylamine derivatives having .beta.2 adrenergic agonist and m3 muscarinic antagonist activities
11/17/2011	CA2799079A1 Tetracycline compositions
11/17/2011	CA2799020A1 Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
11/17/2011	CA2799015A1 Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
11/17/2011	CA2798946A1 Darunavir compositions
11/17/2011	CA2798924A1 Improved methods for preparing squalene
11/17/2011	CA2798874A1 Phenolic compositions derived from apple skin and uses thereof
11/17/2011	CA2798856A1 Immunostimulatory and vaccine compositions
11/17/2011	CA2798831A1 Morpholine compounds as mineralocorticoid receptor antagonists
11/17/2011	CA2798763A1 Compounds useful as inhibitors of atr kinase
11/17/2011	CA2798760A1 2-aminopyridine derivatives useful as inhibitors of atr kinase
11/17/2011	CA2798697A1 Lipoic acid and nitroxide derivatives and uses thereof
11/17/2011	CA2798490A1 Nitrogen heterocyclic compounds useful as pde10 inhibitors
11/17/2011	CA2798401A1 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
11/17/2011	CA2798375A1 Substituted heterocyclyl benzyl pyrazoles, and use thereof
11/17/2011	CA2798068A1 New dosage form for cineole
11/17/2011	CA2795438A1 Method of detecting and profiling progression of the risk of neurodegenerative diseases
11/17/2011	CA2793545A1 Treatment methods
11/17/2011	CA2790847A1 Fused bicyclic kinase inhibitors
11/16/2011	EP2386861A2 Cross-ß structure binding compounds
11/16/2011	EP2386859A2 Diagnostic tumor markers
11/16/2011	EP2386659A2 Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof
11/16/2011	EP2386658A2 Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof
11/16/2011	EP2386657A2 Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof
11/16/2011	EP2386656A2 Genetic Polymorphisms Associated with Cardiovascular Disorders and Drug Response, Methods of Detection and Uses Thereof
11/16/2011	EP2386640A2 Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
11/16/2011	EP2386636A2 ENA nucleic acid drugs modifying splicing in mRNA precursor
11/16/2011	EP2386630A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
11/16/2011	EP2386629A1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
11/16/2011	EP2386565A2 Compounds and methods to inhibit or augment an inflammatory response
11/16/2011	EP2386560A1 Crystalline clopidogrel naphthalenesulfonate hydrate, method for preparing same and pharmaceutical composition containing same
11/16/2011	EP2386559A1 Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use
11/16/2011	EP2386558A1 CGRP antagonists
11/16/2011	EP2386557A1 Novel substituted imidazoquinolines
11/16/2011	EP2386556A1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands
11/16/2011	EP2386555A1 New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
11/16/2011	EP2386554A1 Compounds active at the histamine H3 receptor
11/16/2011	EP2386553A1 Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses
11/16/2011	EP2386551A1 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

1 ... 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 ... 7860